# Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists

> **NCT05338632** · PHASE1 · RECRUITING · sponsor: **Leiden University Medical Center** · enrollment: 24 (estimated)

## Conditions studied

- Opioid Induced Respiratory Depression
- Chronic Opioid Use

## Interventions

- **DRUG:** Narcan 40 MG/ML Nasal Spray
- **DRUG:** Naloxone Hydrochloride
- **DRUG:** Nalmefene HCl injection

## Key facts

- **NCT ID:** NCT05338632
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-24
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338632, "Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05338632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*